ES3039265T3 - Phytoecdysones for use in the prevention of muscle strength loss during immobilisation - Google Patents

Phytoecdysones for use in the prevention of muscle strength loss during immobilisation

Info

Publication number
ES3039265T3
ES3039265T3 ES19711977T ES19711977T ES3039265T3 ES 3039265 T3 ES3039265 T3 ES 3039265T3 ES 19711977 T ES19711977 T ES 19711977T ES 19711977 T ES19711977 T ES 19711977T ES 3039265 T3 ES3039265 T3 ES 3039265T3
Authority
ES
Spain
Prior art keywords
immobilization
muscle
days
compound
decahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19711977T
Other languages
English (en)
Spanish (es)
Inventor
Pierre Dilda
Mathilde Latil
René LAFONT
Stanislas Veillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorbonne Universite
Biophytis SA
Original Assignee
Sorbonne Universite
Biophytis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorbonne Universite, Biophytis SA filed Critical Sorbonne Universite
Application granted granted Critical
Publication of ES3039265T3 publication Critical patent/ES3039265T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES19711977T 2018-02-28 2019-02-20 Phytoecdysones for use in the prevention of muscle strength loss during immobilisation Active ES3039265T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851778A FR3078252B1 (fr) 2018-02-28 2018-02-28 Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
PCT/FR2019/050392 WO2019166717A1 (fr) 2018-02-28 2019-02-20 Phytoecdysones pour leur utilisation dans la prévention de la perte de force musculaire lors d'une immobilisation

Publications (1)

Publication Number Publication Date
ES3039265T3 true ES3039265T3 (en) 2025-10-20

Family

ID=62528604

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19711977T Active ES3039265T3 (en) 2018-02-28 2019-02-20 Phytoecdysones for use in the prevention of muscle strength loss during immobilisation

Country Status (9)

Country Link
US (2) US20210369735A1 (https=)
EP (1) EP3758709B1 (https=)
JP (1) JP7386798B2 (https=)
KR (1) KR20200128058A (https=)
CN (1) CN111954534A (https=)
BR (1) BR112020017492A2 (https=)
ES (1) ES3039265T3 (https=)
FR (1) FR3078252B1 (https=)
WO (1) WO2019166717A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684572A5 (fr) * 1992-04-16 1994-10-31 Jean Louis Connat Nourriture à base d'ecdystéroîdes abaissant la fertilité des parasites hématophages.
AU2003902621A0 (en) * 2003-05-27 2003-06-12 Commonwealth Scientific And Industrial Research Organisation Ecdysone receiptor ligand-binding domain structure
FR2924346B1 (fr) * 2007-11-30 2010-02-19 Inst Biophytis Sas Utilisation de phytoecdysones dans la preparation d'une composition pour agir sur le syndrome metabolique.
EP2265116A4 (en) * 2008-03-14 2013-02-06 Intrexon Corp STEROID LIGANDS AND THEIR USE IN GENE SWITCH MODULATION
RU2390270C1 (ru) * 2009-03-13 2010-05-27 Общество С Ограниченной Ответственностью "Парафарм" Биологически активная добавка к пище
WO2010132982A1 (en) * 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
AU2011343970A1 (en) * 2010-12-13 2013-07-04 Rutgers University Methods of producing and using brassinosteroids to promote growth, repair and maintenance of skeletal muscle and skin
FR2982489B1 (fr) * 2011-11-10 2013-12-27 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans la stabilisation du poids apres un regime amaigrissant
FR2983733B1 (fr) * 2011-12-13 2017-12-22 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans l'amelioration de la qualite musculaire de mammiferes obeses et/ou sarcopeniques
CN102766186B (zh) * 2012-08-03 2015-07-15 玉溪市维和生物技术有限责任公司 富含蜕皮激素的植物标准提取物的制备方法及应用
US20190054093A1 (en) * 2014-04-04 2019-02-21 Nektium Pharma Sl Treatment of sarcopenia with ecdysteroids
FR3021318B1 (fr) * 2014-05-20 2017-04-28 Inst Biophytis Produits derives de la 20-hydroxyecdysone et leur utilisation dans la preparation de medicaments
US9700589B2 (en) * 2015-02-03 2017-07-11 Naturex Sa Compositions and methods for improved muscle metabolism
FR3035105A1 (fr) * 2015-04-16 2016-10-21 Metabrain Res Derives utiles dans le traitement de l'atrophie musculaire
FR3035589B1 (fr) * 2015-04-30 2019-12-13 Biophytis Composition pour la protection des cellules de l'epithelium pigmentaire retinien
CN105343466B (zh) * 2015-11-16 2019-01-18 南阳理工学院 一种治疗冠心病的中药组合物
FR3065644B1 (fr) * 2017-04-28 2020-02-21 Biophytis Extrait de 20-hydroxyecdysone de qualite pharmaceutique, son utilisation et sa preparation
FR3093640B1 (fr) * 2019-03-15 2021-10-01 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires

Also Published As

Publication number Publication date
US20210369735A1 (en) 2021-12-02
US20230158046A1 (en) 2023-05-25
WO2019166717A1 (fr) 2019-09-06
FR3078252B1 (fr) 2020-08-14
CN111954534A (zh) 2020-11-17
EP3758709A1 (fr) 2021-01-06
FR3078252A1 (fr) 2019-08-30
JP2021516228A (ja) 2021-07-01
KR20200128058A (ko) 2020-11-11
JP7386798B2 (ja) 2023-11-27
EP3758709B1 (fr) 2025-07-09
BR112020017492A2 (pt) 2020-12-22
EP3758709C0 (fr) 2025-07-09

Similar Documents

Publication Publication Date Title
JP5992594B2 (ja) 抗炎症可溶フィルム
Reeta et al. Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats
KR101660246B1 (ko) 국소 항염증 조합물
KR100554319B1 (ko) 염증성 질환 치료용 의약의 제조에 있어서 가바펜틴 등의감마-아미노부티르산 동족체의 용도
JP2020055840A (ja) 麻痺を伴わない疼痛緩和のための組成物および方法
ES3039265T3 (en) Phytoecdysones for use in the prevention of muscle strength loss during immobilisation
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
CN113288904B (zh) Mitoquinone在制备预防和/或治疗运动损伤的药物中的应用
ES2881867T3 (es) Composiciones que comprenden geraniol y jengibre seco para uso en el tratamiento del síndrome del intestino irritable
ES2422877A2 (es) Combinación y composición para el tratamiento de obesidad
CN113288890B (zh) N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
EP2978435B1 (en) A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome
Dundar et al. An experimental investigation of the effects of chronic stress on bone-to-implant contact
HU207446B (en) Method for producing medicinal preparation of local use
ES2336786T3 (es) Utilizacion de extractos de ginkgo biloba para favorecer la masa muscular en detrimento de la masa grasa.
RU2040256C1 (ru) Средство для лечения травматического артрита
WO2025186837A1 (en) A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage
CN101134055A (zh) 治疗痔疮的艾炷